logo-loader

Nyota Minerals One2One Investor Presentation 12 November 09

Last updated: 18:00 11 Nov 2009 EST, First published: 19:00 11 Nov 2009 EST

no_picture_pai

Melissa Sturgess, CEO of Nyota Minerals, updates investors at the Proactive Investors One2One Forum on 12th November 2009

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

24 minutes ago